The Adaptor Protein TRIP6 Antagonizes Fas-induced Apoptosis but Promotes Its Effect on Cell Migration

Overview

Journal Mol Cell Biol

Specialty Cell Biology

Date 2010 Sep 30

PMID 20876301

Citations 24

Authors

Yun-Ju Lai

Victor T G Lin

Ying Zheng

Etty N Benveniste

Fang-Tsyr Lin

Affiliations

Soon will be listed here.

Abstract

The Fas/CD95 receptor mediates apoptosis but is also capable of triggering nonapoptotic signals. However, the mechanisms that selectively regulate these opposing effects are not yet fully understood. Here we demonstrate that the activation of Fas or stimulation with lysophosphatidic acid (LPA) induces cytoskeletal reorganization, leading to the association of Fas with actin stress fibers and the adaptor protein TRIP6. TRIP6 binds to the cytoplasmic juxtamembrane domain of Fas and interferes with the recruitment of FADD to Fas. Furthermore, through physical interactions with NF-κB p65, TRIP6 regulates nuclear translocation and the activation of NF-κB upon Fas activation or LPA stimulation. As a result, TRIP6 antagonizes Fas-induced apoptosis and further enhances the antiapoptotic effect of LPA in cells that express high levels of TRIP6. On the other hand, TRIP6 promotes Fas-mediated cell migration in apoptosis-resistant glioma cells. This effect is regulated via the Src-dependent phosphorylation of TRIP6 at Tyr-55. As TRIP6 is overexpressed in glioblastomas, this may have a significant impact on enhanced NF-κB activity, resistance to apoptosis, and Fas-mediated cell invasion in glioblastomas.

Citing Articles

Glucose oxidation-dependent survival of activated B cells provides a putative novel therapeutic target for lupus treatment.

Wilson J, Wei J, Daamen A, Sears J, Bechtel E, Mayberry C iScience. 2023; 26(9):107487.

PMID: 37636066 PMC: 10448027. DOI: 10.1016/j.isci.2023.107487.

Amplicon Contains Cyclic AMP Response Element-Driven Gene in Taxane-Resistant MCF-7 Breast Cancer Sublines.

Daniel P, Balusikova K, Vaclavikova R, Seborova K, Ransdorfova S, Valerianova M Genes (Basel). 2023; 14(2).

PMID: 36833223 PMC: 9957548. DOI: 10.3390/genes14020296.

Synthesis and Significance of Arachidonic Acid, a Substrate for Cyclooxygenases, Lipoxygenases, and Cytochrome P450 Pathways in the Tumorigenesis of Glioblastoma Multiforme, Including a Pan-Cancer Comparative Analysis.

Korbecki J, Rebacz-Maron E, Kupnicka P, Chlubek D, Baranowska-Bosiacka I Cancers (Basel). 2023; 15(3).

PMID: 36765904 PMC: 9913267. DOI: 10.3390/cancers15030946.

ST6Gal1: Oncogenic signaling pathways and targets.

Gc S, Bellis S, Hjelmeland A Front Mol Biosci. 2022; 9:962908.

PMID: 36106023 PMC: 9465715. DOI: 10.3389/fmolb.2022.962908.

Expression of tripartite motif-containing 44 and its prognostic and clinicopathological value in human malignancies:a meta-analysis.

Xiao G, Yang Q, Bao Z, Mao H, Zhang Y, Lin S BMC Cancer. 2020; 20(1):525.

PMID: 32503466 PMC: 7275359. DOI: 10.1186/s12885-020-07014-w.

References

E S, Lai Y, Tsukahara R, Chen C, Fujiwara Y, Yue J . Lysophosphatidic acid 2 receptor-mediated supramolecular complex formation regulates its antiapoptotic effect. J Biol Chem. 2009; 284(21):14558-71. PMC: 2682904. DOI: 10.1074/jbc.M900185200. View

Ivanov V, Lopez Bergami P, Maulit G, Sato T, Sassoon D, Ronai Z . FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol Cell Biol. 2003; 23(10):3623-35. PMC: 164761. DOI: 10.1128/MCB.23.10.3623-3635.2003. View

Stettner M, Wang W, Nabors L, Bharara S, Flynn D, Grammer J . Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res. 2005; 65(13):5535-43. DOI: 10.1158/0008-5472.CAN-04-3688. View

Du J, Bernasconi P, Clauser K, Mani D, Finn S, Beroukhim R . Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol. 2008; 27(1):77-83. PMC: 3057643. DOI: 10.1038/nbt.1513. View

Yonehara S, Ishii A, Yonehara M . A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med. 1989; 169(5):1747-56. PMC: 2189304. DOI: 10.1084/jem.169.5.1747. View

Beier C, Schulz J . CD95/Fas in the brain--not just a killer. Cell Stem Cell. 2009; 5(2):128-30. DOI: 10.1016/j.stem.2009.07.008. View

Boldin M, Goncharov T, Goltsev Y, Wallach D . Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell. 1996; 85(6):803-15. DOI: 10.1016/s0092-8674(00)81265-9. View

Parlato S, Giammarioli A, Logozzi M, Lozupone F, Matarrese P, Luciani F . CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway. EMBO J. 2000; 19(19):5123-34. PMC: 302100. DOI: 10.1093/emboj/19.19.5123. View

Strasser A, Jost P, Nagata S . The many roles of FAS receptor signaling in the immune system. Immunity. 2009; 30(2):180-92. PMC: 2956119. DOI: 10.1016/j.immuni.2009.01.001. View

10.

Peter M, Krammer P . The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003; 10(1):26-35. DOI: 10.1038/sj.cdd.4401186. View

11.

Xu J, Lai Y, Lin W, Lin F . TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor. J Biol Chem. 2003; 279(11):10459-68. PMC: 3904432. DOI: 10.1074/jbc.M311891200. View

12.

Husain N, Chiocca E, Rainov N, Louis D, Zervas N . Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol. 1998; 95(3):287-90. DOI: 10.1007/s004010050799. View

13.

Li L, Bin L, Li F, Liu Y, Chen D, Zhai Z . TRIP6 is a RIP2-associated common signaling component of multiple NF-kappaB activation pathways. J Cell Sci. 2005; 118(Pt 3):555-63. DOI: 10.1242/jcs.01641. View

14.

Kischkel F, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer P . Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995; 14(22):5579-88. PMC: 394672. DOI: 10.1002/j.1460-2075.1995.tb00245.x. View

15.

Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, Kitayama J . Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem. 2006; 281(25):17492-17500. DOI: 10.1074/jbc.M601803200. View

16.

Chastre E, Abdessamad M, Kruglov A, Bruyneel E, Bracke M, Di Gioia Y . TRIP6, a novel molecular partner of the MAGI-1 scaffolding molecule, promotes invasiveness. FASEB J. 2008; 23(3):916-28. DOI: 10.1096/fj.08-106344. View

17.

Murthy K, Clark K, Fortin Y, Shen S, Banville D . ZRP-1, a zyxin-related protein, interacts with the second PDZ domain of the cytosolic protein tyrosine phosphatase hPTP1E. J Biol Chem. 1999; 274(29):20679-87. DOI: 10.1074/jbc.274.29.20679. View

18.

Nozell S, Laver T, Moseley D, Nowoslawski L, De Vos M, Atkinson G . The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes. Mol Cell Biol. 2008; 28(21):6632-45. PMC: 2573235. DOI: 10.1128/MCB.00697-08. View

19.

Nomura N, Nomura M, Sugiyama K, Hamada J . Src regulates phorbol 12-myristate 13-acetate-activated PKC-induced migration via Cas/Crk/Rac1 signaling pathway in glioblastoma cells. Int J Mol Med. 2007; 20(4):511-9. View

20.

Yi J, Kloeker S, Jensen C, Bockholt S, Honda H, Hirai H . Members of the Zyxin family of LIM proteins interact with members of the p130Cas family of signal transducers. J Biol Chem. 2002; 277(11):9580-9. DOI: 10.1074/jbc.M106922200. View